The physostigmine depolarization potentiating effect of salicylate in frog skeletal muscle.
1) The frog's sartorius muscle was depolarized depending on the degree of concentration 2--4 times more intensely by physostigmine salicylate than by physostigmine sulphate. 2) In normal Ringer's solution, 1 mM physostigmine salicylate decreased the sensitivity of the membrane to potassium depolarization by about 90%. Under similar experimental conditions, physostigmine sulphate and Na salicylate, respectively, decrease the sensitivity of the membrane to potassium depolarization by about 30%. 3) The difference manifested in the depolarizing effect of salicylate and other physostigmine salts (chloride, sulphate, phosphate, formiate, acetate, monochloracetate, benzoate and para-oxy-benzoate) is expressed already at 1 mM concentration (about 10-fold), if the muscle had been equilibrated in chloride-free glucuronate or sulphate milieu. 4) The depolarization develops slowly. It takes 30--60 minutes for the new steady state to develop even in the superficial sartorius fibres. If depolarization has reached its maximum on an average 100 mV, the membrane potential remains unchanged for hours. 5) Depolarization ensues at an unchanged degree in the presence of Na-free (choline) Ringer as well as in the presence of 2X10(-8) g/ml tetrodotoxin; therefore, it is not a Na-dependent process. 6) Under the influence of 1 mM physostigmine salicylate the membrane's resistance to the inward potassium current increased about twofold, while the increase was only 15% to the outward potassium current. It is assumed that the salicylate anion is characteristically capable of potentiating the decreasing effect of physostigmine on potassium permeability, though the role of the metabolic effect of salicylate cannot be excluded.
D000818:Animals; D001001:Anura; D002463:Cell Membrane Permeability / Q000187:drug effects; D004357:Drug Synergism; D004553:Electric Conductivity; D006614:Hindlimb; D008564:Membrane Potentials / Q000187:drug effects; D009132:Muscles / Q000187:drug effects* / Q000502:physiology; D010830:Physostigmine / Q000494:pharmacology*; D011188:Potassium / Q000378:metabolism / Q000494:pharmacology; D012459:Salicylates / Q000494:pharmacology*; D012964:Sodium / Q000494:pharmacology; D013431:Sulfates / Q000494:pharmacology
D012459:Salicylates; D013431:Sulfates; D012964:Sodium; D010830:Physostigmine; D011188:Potassium